Track Biolamina
— get Other Fintech Category deals in free daily digest
Overview
Biolamina, a Stockholm-based biotech, secured €20 million in venture debt from the European Investment Bank to enhance cell therapies for chronic diseases. This funding will aid in scaling production and expanding their laminin-based cell culture solutions, crucial for drug testing and treatment development.
Products
Loading...
Recent Deals
Investors: European Investment Bank
Biolamina, a Stockholm-based biotech, secured €20 million in venture debt from the European Investment Bank to enhance cell therapies for chronic diseases. This funding will aid in scaling production and expanding their laminin-based cell culture solutions, crucial for drug testing and treatment development.